Table 3 Treatment exposure
N (%) | ||
|---|---|---|
On treatment | 8 | (14) |
Discontinuation | 47 | (85) |
Refractory | 42 | (76) |
Intolerant | 3 | (5) |
Conversion surgery | 1 | (2) |
Initial dose reduction either nanoliposomal irinotecan or 5-FU | 31 | (56) |
UGT1A1 not available at the initial administration | 8* | (15) |
Age | 10 | (18) |
PS | 3 | (5) |
Others | 10 | (18) |
Dose reduction after one dose | 18 | (33) |
Reasons for dose reduction | ||
Fatigue | 10 | (18) |
Nausea | 6 | (11) |
Anorexia | 6 | (11) |
Diarrhea | 2 | (4) |
Others | 2 | (4) |
Post-treatment† | 22 | (40) |
FOLFOX | 20 | (36) |
S-1 | 2 | (4) |
GEM + nab-PTX | 1 | (2) |
FOLFIRI | 1 | (2) |